Pages that link to "Q38862525"
Jump to navigation
Jump to search
The following pages link to Recent advances in therapy of chronic lymphocytic leukaemia (Q38862525):
Displaying 10 items.
- Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number (Q33798525) (← links)
- Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells (Q36296595) (← links)
- In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells (Q37432558) (← links)
- Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey (Q37631854) (← links)
- Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future (Q38738661) (← links)
- Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. (Q47120488) (← links)
- Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study (Q47185917) (← links)
- Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol α-bisabolol, a dual proapoptotic and antiautophagic agent. (Q55053416) (← links)
- Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia (Q58764409) (← links)
- Ailanthone induces autophagic and apoptotic cell death in human promyelocytic leukemia HL-60 cells. (Q64947455) (← links)